Early Outcomes After Initiation of Faricimab in Patients With Diabetic Macular Edema.

IF 0.9 4区医学 Q4 OPHTHALMOLOGY

Ophthalmic surgery, lasers & imaging retina Pub Date : 2025-05-15 DOI:10.3928/23258160-20250304-01

Durga S Borkar, David C Tabano, Ferhina S Ali, Theodore Leng, Vincent Garmo, Ayesha Ahmed, Rachel Myers, Jacqueline K Shaia, Giulio Barteselli, Rishi P Singh

{"title":"Early Outcomes After Initiation of Faricimab in Patients With Diabetic Macular Edema.","authors":"Durga S Borkar, David C Tabano, Ferhina S Ali, Theodore Leng, Vincent Garmo, Ayesha Ahmed, Rachel Myers, Jacqueline K Shaia, Giulio Barteselli, Rishi P Singh","doi":"10.3928/23258160-20250304-01","DOIUrl":null,"url":null,"abstract":"Background and objective: This study evaluated treatment patterns and outcomes among patients with diabetic macular edema (DME) treated with the bispecific antibody faricimab in routine clinical practice in the United States.Patients and methods: FARETINA-DME was a retrospective study among patients with DME initiating faricimab from February 2022 to June 2023 identified from the United States IRIS® Registry.Results: Four thousand five hundred fourteen (4,514) patients (6,204 eyes) previously treated with anti-vascular endothelial growth factor (anti-VEGF) therapy and 691 treatment-naïve patients (851 eyes) were included. In previously treated eyes, mean ± SD visual acuity was 64.0 ± 18.3 letters at index and 65.3 ± 19.0 at faricimab injection 4. In treatment-naïve eyes, visual acuity improved from 60.3 ± 19.8 to 63.9 ± 18.5 letters (P < 0.01). Mean ± SD central subfield thickness improved from 364.3 ± 132.2 to 330.1 ± 121.2 μm in previously treated eyes and 359.6 ± 115.0 to 307.4 ± 114.6 μm in treatment-naïve eyes (both P < 0.01).Conclusions: In patients with DME receiving faricimab, visual acuity was maintained in previously treated and improved in treatment-naïve eyes. Both groups had anatomical improvement. [Ophthalmic Surg Lasers Imaging Retina 2025;56:XX-XX.].","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"1-9"},"PeriodicalIF":0.9000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic surgery, lasers & imaging retina","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/23258160-20250304-01","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objective: This study evaluated treatment patterns and outcomes among patients with diabetic macular edema (DME) treated with the bispecific antibody faricimab in routine clinical practice in the United States.

Patients and methods: FARETINA-DME was a retrospective study among patients with DME initiating faricimab from February 2022 to June 2023 identified from the United States IRIS^® Registry.

Results: Four thousand five hundred fourteen (4,514) patients (6,204 eyes) previously treated with anti-vascular endothelial growth factor (anti-VEGF) therapy and 691 treatment-naïve patients (851 eyes) were included. In previously treated eyes, mean ± SD visual acuity was 64.0 ± 18.3 letters at index and 65.3 ± 19.0 at faricimab injection 4. In treatment-naïve eyes, visual acuity improved from 60.3 ± 19.8 to 63.9 ± 18.5 letters (P < 0.01). Mean ± SD central subfield thickness improved from 364.3 ± 132.2 to 330.1 ± 121.2 μm in previously treated eyes and 359.6 ± 115.0 to 307.4 ± 114.6 μm in treatment-naïve eyes (both P < 0.01).

Conclusions: In patients with DME receiving faricimab, visual acuity was maintained in previously treated and improved in treatment-naïve eyes. Both groups had anatomical improvement. [Ophthalmic Surg Lasers Imaging Retina 2025;56:XX-XX.].

查看原文本刊更多论文

法利昔单抗治疗糖尿病性黄斑水肿的早期疗效。

背景和目的：本研究评估了在美国常规临床实践中使用双特异性抗体法利昔单抗治疗糖尿病性黄斑水肿（DME）患者的治疗模式和结果。患者和方法：FARETINA-DME是一项回顾性研究，研究对象为从美国IRIS®注册中心筛选的2022年2月至2023年6月开始使用faricimab的DME患者。结果：纳入4,514例（6,204只眼）先前接受抗血管内皮生长因子（anti-VEGF）治疗的患者和691例treatment-naïve患者（851只眼）。在先前治疗的眼睛中，平均±SD视力指数为64.0±18.3个字母，法利西单抗注射4时为65.3±19.0。treatment-naïve组视力由60.3±19.8个字母提高到63.9±18.5个字母（P < 0.01）。先前治疗眼的中心子野厚度平均值±SD从364.3±132.2 μm提高到330.1±121.2 μm， treatment-naïve眼的平均值为359.6±115.0 μm提高到307.4±114.6 μm （P < 0.01）。结论：在接受faricimab治疗的DME患者中，treatment-naïve眼睛的视力维持在先前治疗的水平并有所改善。两组解剖结构均有改善。[眼科外科激光成像视网膜2025；56:XX-XX]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmic surgery, lasers & imaging retina OPHTHALMOLOGY-SURGERY

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： OSLI Retina focuses exclusively on retinal diseases, surgery and pharmacotherapy. OSLI Retina will offer an expedited submission to publication effort of peer-reviewed clinical science and case report articles. The front of the journal offers practical clinical and practice management features and columns specific to retina specialists. In sum, readers will find important peer-reviewed retina articles and the latest findings in techniques and science, as well as informative business and practice management features in one journal.